

tram trinh
tram trinh
Independent Board Director · Certified Chair™ Board Advisor
Fractional Executive · Founder & President, Vitanlink
Helping PE-backed and founder-led B2B health tech maximize value through international expansion ahead of exits
MedTech · Consumer Health · AI | North America, Europe and Asia
Two exits totaling ~$6.2B · 50+ companies advised · €100M+ value created
From Fortune 50 to founder-led companies


Tram Trinh founding member, LPEA INED Committee, October 2022
About
Tram Trinh brings 30+ years of board-level leadership across MedTech, Consumer Health and AI in North America, Europe and Asia, supporting companies at their most pivotal moments: a sale, a management transition, the launch of a foreign group's European subsidiary or a carve-out, often prepared by opening new markets. A builder and connector by nature, she aligns board strategy with shareholder interests to drive value creation while mitigating legal and financial risk.
She works in three capacities: independent board director, Certified Chair™ board advisor for companies of €10-50M, and fractional executive (CBO or Country CEO) for companies of €20-200M, across publicly traded, family-owned, founder-led, PE-backed and venture-backed companies in health tech and AI.Through Vitanlink, the platform she founded in 2013, she helps VC- and PE-backed and founder-led B2B health tech companies maximize value ahead of a sale or a management transition, by building, securing and transferring it, notably through cross-border expansion. Her dual perspective combines an operator's view (she co-founded three ventures, led P&Ls and expanded the market reach of corporate-group subsidiaries in Western Europe and Asia) with financial, legal and governance oversight.
She led commercial and profitability transformations in two businesses later sold for ~$6.2B:
– As CEO France and EMEA Board Director at Welch Allyn (then family-owned, EMEA P&L ~€400M), she led the commercial transformation into connected health and aligned the family shareholders with the new go-to-market. The company was acquired by NYSE-listed Hill-Rom (later Baxter) in 2015 for ~$2.05B.
– As EMEA Management Board Member at Johnson & Johnson Ortho-Clinical Diagnostics (earlier Market Development Director and Head of Marketing Services International), she drove the pricing and operational strategy that laid the groundwork for its ~$4.15B divestiture to The Carlyle Group in 2014. A single
pricing initiative generated $35M of global gross profit in one year, and she delivered $70M of incremental revenue opportunities n China.
Through Vitanlink, she has advised 50+ founder-led and PE/VC-backed companies at board and operating level, contributing to €100M+ in value created. She has served as Fractional CBO and Fractional Country CEO for VC- and PE-backed and privately owned companies, and is Senior M&A Advisor at Alantra, Board Advisor at
Vivaltes and Advisory Board Member at The Sabi. She also serves on the iNED Committee of the LPEA M&A Club and the EHS Law Committee of the IBA. Endeavor Global Network CEOs rate her a top healthcare mentor (9+/10).She holds an MBA (McGill), an LL.M. in International Financial Law (King's College London), an active US CPA license (New Hampshire), the Financial Times Non-Executive Director Diploma, the Private Company Governance certificate (PDA) and the Certified Chair™ credential from the Advisory Board Centre. She
received the J&J Standards of Leadership award twice (2002, 2005).French-born,she has lived and worked in 15+ cities, is based in Paris, and speaks French, English, German and Vietnamese.
aRTICLES & insights
AllCREATE OPPORTUNITIESLEAD WITH AUTHENTICITYINDEPENDENT DIRECTORSHIP EXCELLENCE
© 2026